Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

COPD treatment: CDSCO nod to AstraZeneca India to market triple drug combination inhalation aerosol

Ruchika Sharma15 Dec 2023 4:30 PM IST

Bangalore: Biopharmaceutical company AstraZeneca India has announced that it has received Central Drugs Standard Control Organisation (CDSCO)...

European Commission authorises ViiV Healthcare Vocabria plus Rekambys for HIV treatment in adolescents

Zydus Lifesciences bags USFDA nod for HIV-1 drug Darunavir

Ruchika Sharma15 Dec 2023 3:00 PM IST

Darunavir must be -co-administered with Ritonavir and with other antiretroviral agents.

Cipla to further invest Rs 42 crore in GoApptiv

Ruchika Sharma15 Dec 2023 1:30 PM IST

Mumbai: Cipla Limited has announced that it has agreed to further invest Rs 42 crore (approx.) in digital tech company GoApptiv Private Limited.This...

Caplin Steriles gets USFDA nod for Procainamide Hydrochloride Injection for treating abnormal heart rhythm

Merck Welireg gets USFDA approval for kidney cancer

Ruchika Sharma15 Dec 2023 12:30 PM IST

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved...

Lupin secures SBTi validation for emission reduction targets

Lupin Diagnostics unveils Regional Reference Laboratory in Chennai

Ruchika Sharma15 Dec 2023 11:30 AM IST

Chennai: Global pharma major Lupin Limited has announced the launch of its new state-of-the-art Regional Reference Laboratory in Chennai, Tamil...

USFDA nod to Zydus Lifesciences cancer drug Cyclophosphamide

Ruchika Sharma14 Dec 2023 3:24 PM IST

Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cells.

CDSCO Panel Denies Trial Waiver for Atropine, Asks Sun Pharma to Conduct Phase III Study

Sun Pharma Ilumetri now included in category B of China National Reimbursement Drug List

Ruchika Sharma14 Dec 2023 2:43 PM IST

ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Biocon associate co Bicara Therapeutics raises over Rs 1375 crore in series C financing

Ruchika Sharma14 Dec 2023 1:30 PM IST

Boston: Bicara Therapeutics, an associate company of Biocon Limited, has announced the completion of an oversubscribed $165 million Series C...

Medtronic bags USFDA nod for PulseSelect Pulsed Field Ablation System to treat atrial fibrillation

Ruchika Sharma14 Dec 2023 12:30 PM IST

The PulseSelect PFA system was engineered with differentiated safety features and provides rapid, effective pulmonary vein isolation through...

No shortage of TB drugs in India: Govt

Ruchika Sharma14 Dec 2023 11:30 AM IST

New Delhi: The Ministry of Health & Family Welfare has informed that there is no shortage of anti-tuberculosis drugs in the country....

State-Wide Immunization Drive in Haryana Targets High-Risk Areas

Japan accepts GSK Arexvy regulatory application to prevent RSV disease in adults aged 50-59 at increased risk

Ruchika Sharma14 Dec 2023 10:00 AM IST

London: GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a regulatory application to extend...

Pfizer discontinues development of danuglipron for chronic weight management

Pfizer forecasts 2024 revenue below Wall Street expectations

Ruchika Sharma13 Dec 2023 5:40 PM IST

New York: Pfizer on Wednesday forecast 2024 revenue that was below Wall Street expectations and raised its cost-cut target by $500 million.The...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok